drugset / Trial / NCT01808144

Lesinurad and Febuxostat Combination Extension Study in Gout

NCT01808144

Phase 3 Completed 196 enrolled Ardea Biosciences, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will assess the serum uric acid lowering effects and safety of lesinurad in combination with febuxostat over a long-term timeframe.

Timeline

Start
2013-03-01
Primary completion
2016-08-09
Completion
2016-10-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Febuxostat Small molecule 80 mg
Subject Lesinurad Small molecule 200 mg
Subject Lesinurad Small molecule 400 mg

Indications